^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cyclophosphamide

    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    17h
    An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropathy (clinicaltrials.gov)
    P1, N=36, Recruiting, Changhai Hospital | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • fludarabine IV • KN5501
    18h
    GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=9, Not yet recruiting, Chinese PLA General Hospital
    New P1 trial
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    19h
    NADERIN-BC: Prophylaxis of Hematologic Complications With Naderin in First-Line Breast Cancer Chemotherapy (clinicaltrials.gov)
    P2/3, N=79, Completed, MIPO Clinic
    New P2/3 trial
    |
    doxorubicin hydrochloride • cyclophosphamide
    19h
    Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=60, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Aug 2026 --> May 2026
    Enrollment open • Trial initiation date • Pan tumor
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    cyclophosphamide • fludarabine IV
    1d
    Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer (clinicaltrials.gov)
    P2, N=92, Completed, University of Nebraska | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Nov 2025
    Trial completion • Trial completion date
    |
    paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Trazimera (trastuzumab-qyyp)
    1d
    Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells (clinicaltrials.gov)
    P1, N=42, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: May 2028 --> May 2030 | Trial primary completion date: May 2026 --> May 2028
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    cyclophosphamide • fludarabine IV • CAR.B7-H3 T
    1d
    JKART-1: Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, Kite, A Gilead Company | Trial primary completion date: Nov 2025 --> Jul 2027
    Trial primary completion date
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14)
    |
    cyclophosphamide • fludarabine IV • Tecartus (brexucabtagene autoleucel)
    1d
    Plerixafor Plus G-CSF Versus Etoposide Combined With Cyclophosphamide and G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Single Center Observational Propensity Score-Matched Cohort Study. (PubMed, J Clin Apher)
    PXF + G-CSF is a more effective and less toxic mobilizing agent than the chemotherapy-based regimen (EC + G-CSF), and is associated with faster hematopoietic reconstruction without increasing the risk of tumor progression. This regimen may be considered a valuable option for stem cell mobilization.
    Clinical • Observational data • Journal
    |
    CD34 (CD34 molecule)
    |
    cyclophosphamide • etoposide IV • plerixafor
    1d
    ICG415-AML-01: Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=18, Recruiting, iCell Gene Therapeutics
    New P1 trial
    |
    CD8 (cluster of differentiation 8) • CD33 (CD33 Molecule) • CD4 (CD4 Molecule)
    |
    cyclophosphamide • fludarabine IV
    2d
    Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients (clinicaltrials.gov)
    P1, N=9, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression • DLL3 positive
    |
    cyclophosphamide • fludarabine IV
    2d
    Lycopene as a Multi-Target Inhibitor of Ferroptosis: A Narrative Review of Preclinical Evidence and Clinical Prospects. (PubMed, Food Chem Toxicol)
    The therapeutic potential of lycopene is evaluated in polycystic ovary syndrome (PCOS), non-alcoholic steatohepatitis (NASH), neurodegenerative disorders, cancer, cardiovascular diseases, and injuries induced by environmental toxicants including atrazine, cadmium, cisplatin, and cyclophosphamide. Future research priorities include developing bioavailable formulations, conducting target identification studies, and validating ferroptosis-specific biomarkers. Currently, the primary contribution of lycopene research remains in mechanistic preclinical studies, and clinical recommendations are premature.
    Preclinical • Review • Journal
    |
    NCOA4 (Nuclear Receptor Coactivator 4) • GPX4 (Glutathione Peroxidase 4)
    |
    cisplatin • cyclophosphamide
    2d
    A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=31, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2029 --> Dec 2028 | Trial primary completion date: Jun 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • HLA-G (Major Histocompatibility Complex, Class I, G)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    cyclophosphamide • fludarabine IV • IVS-3001